Post-COVID-19-Associated Mucormycosis: An Observational Study with Clinical and Radiographical Presentation

Introduction: Mucormycosis is an emerging fungal infection increasingly affecting COVID-19 patients, especially those with diabetes. Rhizopus oryzae thrives in high-iron conditions, causing angioinvasion and tissue necrosis. As reported in 31%–50% of cases during COVID-19’s second wave, early diagnosis and management are crucial to prevent severe complications and fatalities. Materials and Methods: We conducted a multicentre retrospective study to analyse the clinicoepidemiological profile of mucormycosis in COVID-19 and non-COVID-19 patients. Amongst 492 screened cases, 47 confirmed mucormycosis patients were included. Data collection focused on demographics, clinical features, comorbidities, risk factors, treatments and diagnostic findings. Results: We conducted a multicentre retrospective study on 47 COVID-19-associated mucormycosis (CAM) patients. Amongst them, 25 had a history of COVID-19 with mucormycosis symptoms, while 15 showed no significant COVID-19 history. The study aimed to provide clinicoepidemiological data on CAM in acute and recent COVID-19 cases. Conclusion: Mucormycosis is a rapidly spreading disease affecting COVID-19 patients, especially those on prolonged corticosteroids or with diabetes. This study highlights clinical and radiographic features, emphasising early diagnosis. A larger multicentre study is recommended.